8-K: Zomedica Reports Record Revenue for Q4 and Full Year 2024, Bolstered by Diagnostics Growth

Zomedica announces record revenue of $7.9 million for the fourth quarter and $27.3 million for the full year 2024, driven by strong growth in its Diagnostics segment and a 70% gross margin.

Summary

• Zomedica Corp. reported its financial results for the fourth quarter and year ended December 31, 2024.
• The company achieved record revenue of $7.9 million for the fourth quarter, an 8% organic growth compared to the same period in 2023.
• The Diagnostics segment experienced a 109% year-over-year increase, primarily due to the adoption of TRUFORMA and VETGuardian product lines.
• Gross margin for the fourth quarter was 70.3%.
• Net loss for the quarter was $7.2 million, a significant improvement from the $22.4 million loss in the fourth quarter of 2023.
• Adjusted non-GAAP EBITDA loss for the quarter was $5.4 million, compared to $6.7 million in the prior year.
• For the full year 2024, revenue grew by over 8% to $27.3 million, compared to $25.2 million in 2023.
• Diagnostics segment grew by 77% for the year.
• Gross margin for the full year was 70.0%.
• Net loss for the year was $47.0 million, compared to a net loss of $34.5 million in the previous year.
• Adjusted Non-GAAP EBITDA loss for the year was $20.2 million.
• The company had $71.4 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to record revenue, strong gross margins, and improved net loss in Q4. However, the overall net loss for the year and ongoing cash burn temper the enthusiasm.

Positives

• Record revenue achieved for both the fourth quarter and full year 2024.
• Significant growth in the Diagnostics segment, driven by TRUFORMA and VETGuardian product lines.
• Strong gross margin of 70% maintained.
• Improved net loss in the fourth quarter compared to the previous year.
• Healthy cash position of $71.4 million at the end of 2024.
• Expansion into key international markets and new distribution agreements.
• Optimized manufacturing capabilities to support growing demand.

Negatives

• The company experienced a net loss of $47.0 million for the full year 2024.
• Non-GAAP EBITDA loss for the year ended December 31, 2024, was $40.7 million.
• Total cash used during the year was approximately $29.1 million.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties.
• These risks include the outcome of clinical studies, regulatory approvals, and competition from related products.
• Supply chain risks associated with tariff changes could impact the company's ability to supply products.
• The company's ability to achieve commercial success for new products and technologies is uncertain.
• Veterinary acceptance of the company's products and purchase of consumables is not guaranteed.

Future Outlook

Zomedica anticipates that its increased focus on the equine market, new product launches, and the Vetigel distribution agreement will drive new revenue streams in 2025, and the company will leverage its strong balance sheet to add compelling products to its portfolio.

Management Comments

• We wrapped up a strong 2024 with solid performance in the fourth quarter as we posted record revenue, year over year, for the 15th straight quarter, said Larry Heaton, President and Chief Executive Officer of Zomedica.
• 2024 was a transformative year for Zomedica, one which put the company in a fantastic position to drive accelerated revenue growth in 2025 and beyond, continued Mr. Heaton.
• Operationally, we expanded and optimized our manufacturing capabilities, enabling us to support the growing demand for our portfolio while at the same time capturing efficiencies which will help drive us to profitability, continued Mr. Heaton.
• Looking ahead to 2025, we have a number of exciting catalysts that will support our growth trajectory, concluded Mr. Heaton.

Industry Context

Zomedica's focus on the veterinary health market, particularly in diagnostics and therapeutics for equine and companion animals, aligns with the growing demand for advanced veterinary care solutions. The company's expansion into international markets and strategic acquisitions position it to compete effectively in this evolving industry.

Comparison to Industry Standards

• Zomedica's 70% gross margin is strong compared to industry averages for veterinary diagnostics and therapeutics companies.
• Companies like IDEXX Laboratories and Zoetis also operate in the animal health market, but Zomedica focuses on point-of-care diagnostics and therapeutics.
• Zomedica's revenue growth of 8% is moderate compared to some high-growth companies in the diagnostics space, but its focus on profitability and strategic acquisitions could lead to accelerated growth in the future.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and improved Q4 net loss.
• Veterinarians may benefit from the company's innovative diagnostic and therapeutic solutions.
• Employees may see opportunities for growth as the company expands its operations.

Next Steps

• Zomedica will focus on the equine market with new product launches and sales roles.
• The company will leverage its balance sheet for strategic acquisitions.
• Zomedica will continue to expand internationally.

Key Dates

Keywords

Zomedica, veterinary health, diagnostics, therapeutics, revenue, gross margin, financial results, TRUFORMA, VETGuardian, PulseVet